54 results
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
10 May 19
Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update
7:38am
DEXTENZA (dexamethasone ophthalmic insert):
· Completed the initial hiring of its sales management, key account managers, medical science liaisons … in unallocated costs, primarily personnel costs associated with additional hiring, and costs associated with the Company’s pipeline programs as well
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 Mar 19
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2018 Financial Results and Business Update
4:06pm
has completed
the hiring of its sales management team and is actively recruiting for the rest of its field organization. Ocular plans to launch … unallocated other costs, primarily in personnel costs, consulting services, outside testing expenses, and costs associated with additional hiring.
· Selling
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
12 Mar 20
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update
4:03pm
primarily by the full impact of the hiring of new members of the commercial team including Key Account Managers, Field Reimbursement Managers and Medical … from $4.9 million in 2018, driven primarily by the hiring of new members of the commercial team, as highlighted above, as well as increased spending
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 Aug 18
Ocular Therapeutix™ Reports Second Quarter 2018 Financial Results and Business Update
4:06pm
versus $8.1 million for the second quarter of 2017 and reflect an increase in compensation costs associated with additional hiring primarily
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 Nov 18
Ocular Therapeutix™ Reports Third Quarter 2018 Financial Results and Business Update
4:08pm
and slightly increased compensation costs associated with additional hiring - primarily in the technical operations and quality departments.
· Selling
8-K
EX-99.1
8bf826n
13 Apr 20
Ocular Therapeutix™ Provides Business Update and Response to COVID-19 Global Pandemic
8:05am
8-K
EX-99.1
ym4ip1g6omx5usnlzik2
7 Aug 19
Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results and Business Update
4:06pm
8-K
EX-99.1
pup55c t83t49
12 Nov 19
Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update
7:20am
8-K
EX-99.1
wnyl 6jg12dz
9 May 22
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
4:05pm
8-K
EX-99.1
b1fuz3yj9xv4o1nu ln
8 May 20
Ocular Therapeutix™ Reports First Quarter 2020 Financial Results and Business Update
7:05am